


# Clock is ticking towards DoA for MDR We are well past two thirds of the MDR implementation period Five notified bodies accredited for MDR Some big notified bodies threw in the towel for MDR and (AI)MDD "How did it get so late so soon? Its night before its June. My goodness how the time has flewn. How did it get so late so soon?" -Dr. Seuss



# Implementation deadlines First companies with up-classified class I devices or missed windows for (AI)MDD recertification are finding that they will not have an MDR certificate in time for DoA • Software, inhalers, reusable surgical instruments Notified bodies try to keep customers in house with Jedi mind trick that all will be well Ehhh – OK, I No panic - we will be MDR accredited in time to certify your product.

Which	What			
Known knowns	MDR text     Rolling Plan that keeps changing     When to apply at notified body for (AI)MDD recert?     Corrigendum – dots, commas and no transition amended			
Known unknowns	Corrigendum no 2 – class Ir but anything else? Common specifications Implementing acts What standards will be harmonised? Alot of guidance (except MDCG stuff on UDI, PRRC, implant card and CAMD Q&A) Eudamed functionality by March 2020 – but which parts? National implementation – but which member states and how? Your notified body accredited to the scope you need? Your notified body ready to accept MDR or MDD cert (re)application? Your notified body not shutting down on you?			
Unknown unknowns	National enforcement in case of     bottleneck induced shortages     notified body failing to deliver MDR certificate timely			
All over the place unpredictably crazy	Brexit – plan for a hard Brexit and have plans B and C     Switzerland and Turkey MRA mechanisms			

## Implementation

- Steady stream of UDI related guidance by MDCG
   Not that helpful PRRC guidance
   Recent SSCP guidance
   More CS are slowly becoming available

- - Annex XVI productsReprocessing
- Implementing decision on expert panels for PFKAS (Procedure Formerly Known As Scrutiny (Clinical Evaluation Consultation Procedure)
- Member States national legislation NL, DE

<b>Exter</b>		- 6 -	 : C
LVIA	16IAN	$\alpha$	IDOC



- Rumor: Corrigendum 2 in the works
  - Will likely concern a 'correction' of article 120 (3) MDR as regards class Ir devices and need to have a Ir certificate by DoA (26 May
- Will likely cover entire soft transition period (26 May 2020 27 May 2024)
- No other extensions foreseen but more persistent rumors
  - Other up-classified class I devices may be covered too

### **Notified bodies landscape**

- MDR : five notified bodies designated, of which sometimes significant scope restrictions

  - E.g. not Annex X (type examination) (BSI and Dekra Germany)
    E.g. not class III devices (IMQ)
    E.g. not breast implants (TUV SUD and Dekra Germany)
    E.g. no active implants (Dekra Germany and TUV Rheinland)
- IVDR: none yet but likely soon
- Rumors rumors 20 NBs designated by the end of the year? More NBs on the way further to the next MDCG meeting

Name	Country
BSI Assurance UK Ltd	United
	Kingdom
DEKRA Certification GmbH	Germany
IMQ ISTITUTO ITALIANO DEL MARCHIO DI QUALITÀ S.P.A.	Italy
TÜV Rheinland LGA Products GmbH	Germany
TÜV SÜD Product Service GmbH Zertifizierstellen	Germany
	BSI Assurance UK Ltd  DEKRA Certification GmbH  IMQ ISTITUTO ITALIANO DEL MARCHIO DI QUALITÀ S.P.A.  TÜV Rheinland LGA Products GmbH

### **Notified bodies landscape**

- Issues start to arise with notified bodies (partially) laying down service in sight of MDR deadline
  - LRQA, UL, AMTAC/Intertek but also others
  - Orphaning not a solution for certificates from UK notified bodies: Commission takes view that hard Brexit ends orphaning by member states
- Notified bodies more and more under capacity pressure
  - Alot of disruptions and certificate issues resulting from lack of capacity (renewal audits missed, sudden extra requirements (especially in clinical) resulting in certificates suspended or not renewed)

•		
•		
,		
•	 	

### **Notified bodies landscape**

- Concept of 'significant change' still not crystalized
  - · Crucial to understand for manufacturers relying on 'soft transition' (2020-2024 exemption under article 120 (3) MDR)
  - Determines M&A structuring for all manufacturers that rely on soft transition
    - anything other than a shares transfer without reorganization will likely cause a significant change that will lead to instant loss of certificates
       Merger pre-closing or post-closing commitments must be

    - Carefully drafted as not to cause a significant change
       Notified bodies have no time to review anything quickly in view of MDR deadlines

### **Notified bodies landscape**

- BSI UK issues first CE certificate under MDR on 2 September 2019 for class IIa device under rule 20 ('simple' inhaler for medicines upclassified from class I)  $\,$
- TUV SUD close on their heels with class III software device

### Consequences of NB ceasing operation

- Notified body gives max 90 days notice
  - After that period, your CE certificates are invalid, no matter the
  - Within that period you must be certified by another notified body

    - Basically impossible to do within 90 days
       Be prepared for orphaning scenario (max 12 months under wings of a competent authority pending NB onboarding)
      - · Make sure you understand the scenarios and conditions (which CA to go to, how does their procedure work, etc.)
- Commission takes the view that a hard Brexit ends all ongoing orphaning of UK NB certificates (AMTAC, LRQA)

### What is there left to do until DoA?

- Know your timing what needs to happen when and have a strategy for
- First NBs are up and running and inventing the wheel in the first product and QMS audits: gain experience from that
  - So far only BSI and TUV SUD seem to have been doing QMS
  - audits on a very limited number of manufacturers

     Approaches seem different based on differences in QMS
  - philosophy
     Exchange experience where possible and engage branch associations to share information

### What is there left to do until DoA?

- Be ready to pivot based on new EU guidance becoming available
- Get the economic operator stuff right

  - PRRC guidance less than comprehensive
     Industry struggles to understand degree of independence required for AR and PRRC
  - New Market Surveillance Regulation (Regulation (EU) 1020/2019
- · Keep your friends (crucial suppliers) close and your notified body closer

### What is there left to do until DoA?

- Be ready to implement Eudamed interfacing and process, have SRN (if OUS Union then have AR with SRN first) and prepare for UDI
  - · Eudamed big bang release not expected anymore
  - Staged release of modules in four batches (March 2020, November 2020, May 2021, May 2022)
     Or: Eudamed may not be ready at all
- Be intelligent with long term commitments (e.g. tenders)
  - Can you guarantee supply of every device over the next five
  - years?
     Do you have a plan B?

### What is there left to do until DoA? Plans B

- Have plan B for scenarios:

  - Hard BrexitSwitzerland and Turkey not being Union under MDR
  - Notified body calamities
    - NB shuts down / certs invalid as a result of Brexit, Swiss or Turkish dependency

      NB misses MDR deadline for either (AI)MDD or MDR
  - Other problems with organisation / certification status that lead to disruptions
    - Understand supply chain and concept of placing on the market

    - Have supply chain scenarios
       Understand national exemption regimes for essential devices

# Thanks for your attention! READ MY BLOG: http://medicaldeviceslegal.com